Is there an association between antiphospholipid antibodies and psoriasis?

Journal of Biological Regulators and Homeostatic Agents

Volumn 22, Issue 3, 2008, Pages 207-210

  Cassano, N ^a   Buquicchio, R ^a   Ranieri, V ^b   Loconsole, F ^a   Vena, Gino A ^a  

^a UNIVERSITY OF BARI   (Italy)

^b POLICLINICO   (Italy)

Author keywords

Anti 2 glycoprotein I antibodies; Anticardiolipin antibodies; Antiphospholipid antibodies; Cardiovascular risk; Lupus anticoagulant; Psoriasis

Indexed keywords

PHOSPHOLIPID ANTIBODY;

BLOOD; FEMALE; HEALTH; HUMAN; IMMUNOLOGY; LETTER; MALE; MIDDLE AGED; PSORIASIS;

ANTIBODIES, ANTIPHOSPHOLIPID; FEMALE; HEALTH; HUMANS; MALE; MIDDLE AGED; PSORIASIS;

EID: 58949086591     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007; 25:529-534. (Pubitemid 350087599)
2. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, Ståhle-Bäckdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19:225-230. (Pubitemid 38461682)
3. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190:1-9. (Pubitemid 44908334)
4. Vanizor Kural B, Orem A, Cimşit G, Uydu HA, Yandi YE, Alver A. Plasma homocysteine and its relationship with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003; 332:23-30. (Pubitemid 36577485)
5. Franck M, Staub HL, Petracco JB, et al. Autoantibodies to the atheroma component beta2-glycoprotein I and risk of symptomatic peripheral artery disease. Angiology 2007; 58:295-302. (Pubitemid 46956259)
6. Marai I, Shechter M, Langevitz P, et al. Anti-cardiolipin antibodies and endothelial function in patients with coronary artery disease. Am J Cardiol 2008; 101:1094-1097.
7. Sherer Y, Shoenfeld Y. Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis? Immunobiology 2003; 207:13-16. (Pubitemid 36285090)
8. Matsuura E, Kobayashi K, Tabuchi M, Lopez LR. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 2006; 45:466-486. (Pubitemid 44331411)
9. Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005; 64:403-407. (Pubitemid 40283050)
10. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulans/Antiphospholipid antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74:1185-1190.
11. Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimm 2000; 15:173-178.
12. Proven A, Bartlett RP, Moder KG, et al. Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies. Mayo Clin Proc 2004; 79:467-475. (Pubitemid 38401766)
13. Ostrowski RA, Robinson JA. Antiphospholipid antibody syndrome and autoimmune diseases. Hematol Oncol Clin North Am 2008; 22:53-65.
14. Kutukculer N, Yuksel SE, Aksu G, Alper S. Autoantibodies other than antineutrophil cytoplasmic antibodies are not positive in patients with psoriasis vulgaris. J Dermatol 2005; 32:179-185.
15. Campanati A, Simonetti O, Silvestri B, et al. Anticardiolipin antibodies expression in psoriasis. G Ital Dermatol Venereol 2004; 139:165-170. (Pubitemid 38868694)